Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 1Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 4Ovarian Neoplasms 1Endometrial Neoplasms 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × onapristone × Breast × Clear all
NCT05618613 2025-05-09

ELONA

Context Therapeutics Inc.

Phase 1/2 Terminated
4 enrolled
Breast

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

NCT04142892 2022-04-01

ONAWA

SOLTI Breast Cancer Research Group

Phase EARLY_PHASE1 Completed
10 enrolled
Breast

Breast Neoplasms

NCT02052128 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers

Arno Therapeutics

Phase 1/2 Unknown
60 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡